Showing results (501-510 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|April 9, 2013
Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysisMay Abdel-Wahab, Jean-Marc Bourque, Yaroslav Pynda, et al.
The Lancet. Oncology|April 9, 2013
Developing cancer control plans in Africa: examples from five countriesDaniela Cristina Stefan, Ahmed M Elzawawy, Hussein M Khaled, et al.
The Lancet. Oncology|April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialRobert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
The Lancet. Oncology|March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trialViviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.
The Lancet. Oncology|March 19, 2013
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trialAdrian S Dobs, Ralph V Boccia, Christopher C Croot, et al.
The Lancet. Oncology|May 4, 2013
Protein phosphatase 2A: a target for anticancer therapyDanilo Perrotti, Paolo Neviani
The Lancet. Oncology|May 4, 2013
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 studyTakashi Seto, Katsuyuki Kiura, Makoto Nishio, et al.
The Lancet. Oncology|February 12, 2013
Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trialMartijn Hgm van der Pas, Eva Haglind, Miguel A Cuesta, et al.
The Lancet. Oncology|February 19, 2013
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trialJohn Fr Robertson, Jean-Marc Ferrero, Hugues Bourgeois, et al.
The Lancet. Oncology|February 2, 2013
Pathobiology of chemotherapy-induced hair lossRalf Paus, Iain S Haslam, Andrey A Sharov, et al.
Pageof 336